The FDA's decision date for Anktiva is Jan 6, 2027, in 65 days. ImmunityBio had about five quarters of cash at its Jun 30 balance. ImmunityBio's Quality Score is 3. Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score. Scores as of 8:12 PM ET, 15 minutes behind.

ImmunityBio (IBRX) · FDA decision date (PDUFA)

ImmunityBio's FDA decision on Anktiva

PDUFA dateJan 6in 65 days Quality Score3Below Average

Share price$7.95-4.10% on the day

Cash runway5quarters of cash

As of Monday's close · Live for Pro members at the open

What the company said

“License Application (sBLA) for ANKTIVA plus BCG in patients with BCG-unresponsive NMIBC with papillary disease without CIS and assigned a PDUFA target action date of January 6, 2027”

PDUFA date, Jan 6, 2027. As ImmunityBio stated in its 8-K of Aug 4, 2026 (the filing).

A PDUFA date is the day the FDA has said it aims to decide on a drug. The FDA can decide earlier, or extend its review, often by three months.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Get an alert before IBRX's FDA date

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

How IBRX's stock moved on its past FDA days, for Pro members. Pro members also see whether its cash lasts past Jan 6, and the FDA calendar with filters and optional alerts.

More on IBRX and the FDA calendar

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Use this page

Kept by Andrew Gomes, Breakaway's founder, from the company's filings on the SEC's EDGAR. Updated Nov 2, 2026.

Download the date's picture (PNG)Free to reuse with a link to this page.

How to cite

Breakaway, ImmunityBio's FDA decision on Anktiva, Nov 2, 2026, getbreakaway.com/biotech/IBRX-anktiva

Journalists: email support@getbreakaway.com for the data behind this page.

The FDA calendar.